1. Parsy CC, Alexandre FR, Bidau V, Bonnaterre F, Brandt G, Caillet C, Cappelle S, Chaves D, Convard T, Derock M, Gloux D, Griffon Y, Lallos LB, Leroy F, Liuzzi M, Loi AG, Moulat L, Chiara M, Rahali H, Roques V, Rosinovsky E, Savin S, Seifer M, Standring D, Surleraux D. Discovery and structural diversity of the hepatitis C virus NS3/4A serine protease inhibitor series leading to clinical candidate IDX320. Bioorg Med Chem Lett. 2015 Nov 15;25(22):5427-36. doi: 10.1016/j.bmcl.2015.09.009. Epub 2015 Sep 5. PMID: 26410074.
2. de Bruijne J, van Vliet A, Weegink CJ, Mazur W, Wiercinska-Drapało A, Simon K, Cholewińska-Szymańska G, Kapocsi J, Várkonyi I, Zhou XJ, Temam MF, Molles J, Chen J, Pietropaolo K, McCarville JF, Sullivan-Bólyai JZ, Mayers D, Reesink H. Rapid decline of viral RNA in chronic hepatitis C patients treated once daily with IDX320: a novel macrocyclic HCV protease inhibitor. Antivir Ther. 2012;17(4):633-42. doi: 10.3851/IMP2078. Epub 2012 Mar 16. PMID: 22427481.
3. Kishimoto M, Doi S, Shimizu J, Lee KJ, Iwasaki T, Miyake Y, Yamada K. Influence of osmolarity of contrast medium and saline flush on computed tomography angiography: comparison of monomeric and dimeric iodinated contrast media with different iodine concentrations at an identical iodine delivery rate. Eur J Radiol. 2010 Oct;76(1):135-9. doi: 10.1016/j.ejrad.2009.05.018. Epub 2009 Jun 6. PMID: 19501993.